{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:43:04Z","timestamp":1787002984541,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK126875"],"award-info":[{"award-number":["R01DK126875"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-54969-6","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T04:56:25Z","timestamp":1733288185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Inhibition of ABCG2 prevents phototoxicity in a mouse model of erythropoietic protoporphyria"],"prefix":"10.1038","volume":"15","author":[{"given":"Junjie","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Ying","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saifei","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6499-8573","authenticated-orcid":false,"given":"Karl E.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7693-5863","authenticated-orcid":false,"given":"Peter","family":"Wipf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2049-7467","authenticated-orcid":false,"given":"Xiaochao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"54969_CR1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1365-2141.1977.tb00637.x","volume":"36","author":"DM Becker","year":"1977","unstructured":"Becker, D. M., Viljoen, J. D., Katz, J. & Kramer, S. Reduced Ferrochelatase Activity: a Defect Common to Porphyria Variegata and Protoporphyria. Br. J. Haematol. 36, 171\u2013179 (1977).","journal-title":"Br. J. Haematol."},{"key":"54969_CR2","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/0020-711X(80)90186-X","volume":"12","author":"S Kramer","year":"1980","unstructured":"Kramer, S. & Viljoen, J. D. Erythropoietic protoporphyria: evidence that it is due to a variant ferrochelatase. Int. J. Biochem. 12, 925\u2013930 (1980).","journal-title":"Int. J. Biochem."},{"key":"54969_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1172\/JCI106474","volume":"50","author":"P Scholnick","year":"1971","unstructured":"Scholnick, P., Marver, H. S. & Schmid, R. Erythropoietic protoporphyria: evidence for multiple sites of excess protoporphyrin formation. J. Clin. Invest. 50, 203\u2013207 (1971).","journal-title":"J. Clin. Invest."},{"key":"54969_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/1011-1344(91)80015-A","volume":"10","author":"A Brun","year":"1991","unstructured":"Brun, A. & Sandberg, S. Mechanisms of photosensitivity in porphyric patients with special emphasis on erythropoietic protoporphyria. J. Photochemistry Photobiol. B Biol. 10, 285\u2013302 (1991).","journal-title":"J. Photochemistry Photobiol. B Biol."},{"key":"54969_CR5","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1042\/bj0750620","volume":"75","author":"C Rimington","year":"1960","unstructured":"Rimington, C. Spectral-absorption coefficients of some porphyrins in the Soret-band region. Biochemical J. 75, 620\u2013623 (1960).","journal-title":"Biochemical J."},{"key":"54969_CR6","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/0009-2614(79)85216-1","volume":"67","author":"GS Cox","year":"1979","unstructured":"Cox, G. S., Whitten, D. G. & Giannotti, C. Interaction of porphyrin and metalloporphyrin excited states with molecular oxygen. Energy-transfer versus electron-transfer quenching mechanisms in photo oxidations. Chem. Phys. Lett. 67, 511\u2013515 (1979).","journal-title":"Chem. Phys. Lett."},{"key":"54969_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/jmd2.12052","volume":"50","author":"H Naik","year":"2019","unstructured":"Naik, H. et al. Evaluating quality of life tools in North American patients with erythropoietic protoporphyria and X\u2010linked protoporphyria. JIMD Rep. 50, 9\u201319 (2019).","journal-title":"JIMD Rep."},{"key":"54969_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-4-19","volume":"4","author":"M Lecha","year":"2009","unstructured":"Lecha, M., Puy, H. & Deybach, J. C. Erythropoietic protoporphyria. Orphanet J. Rare Dis. 4, 19 (2009).","journal-title":"Orphanet J. Rare Dis."},{"key":"54969_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1056\/NEJMoa1411481","volume":"373","author":"JG Langendonk","year":"2015","unstructured":"Langendonk, J. G. et al. Afamelanotide for erythropoietic protoporphyria. N. Engl. J. Med. 373, 48\u201359 (2015).","journal-title":"N. Engl. J. Med."},{"key":"54969_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/17512433.2021.1879638","volume":"14","author":"D Wensink","year":"2021","unstructured":"Wensink, D., Wagenmakers, M. & Langendonk, J. G. Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert Rev. Clin. Pharm. 14, 151\u2013160 (2021).","journal-title":"Expert Rev. Clin. Pharm."},{"key":"54969_CR11","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(09)61925-5","volume":"375","author":"H Puy","year":"2010","unstructured":"Puy, H., Gouya, L. & Deybach, J. C. Porphyrias. Lancet 375, 924\u2013937 (2010).","journal-title":"Lancet"},{"key":"54969_CR12","doi-asserted-by":"crossref","unstructured":"Balwani, M. Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management. Mol. Genet. Metabol. 128, 298\u2013303 (2019).","DOI":"10.1016\/j.ymgme.2019.01.020"},{"key":"54969_CR13","unstructured":"Minder, E. I., Schneider-Yin, X., Steurer, J. & Bachmann, L. M. A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria. Cell Mol. Biol. 55, 84\u201397 (2009)."},{"key":"54969_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-0781.1996.tb00240.x","volume":"12","author":"M Boffa","year":"1996","unstructured":"Boffa, M., Ead, R., Reed, P. & Weinkove, C. A double-blind, placebo-controlled, crossover trial of oral vitamin C in erythropoietic protoporphyria. Photodermatol. Photoimmunol. Photomed. 12, 27\u201330 (1996).","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"54969_CR15","first-page":"244","volume":"10","author":"M Mathews-Roth","year":"1994","unstructured":"Mathews-Roth, M., Rosner, B., Benfell, K. & Roberts, J. A double-blind study of cysteine photoprotection in erythropoietic protoporphyria. Photodermatol. Photoimmunol. Photomed. 10, 244\u2013248 (1994).","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"54969_CR16","doi-asserted-by":"crossref","unstructured":"Hussain, Z., Qi, Q., Zhu, J., Anderson, K. E. & Ma, X. Protoporphyrin IX-induced phototoxicity: Mechanisms and therapeutics. Pharmacol. Ther. 248, 108487 (2023).","DOI":"10.1016\/j.pharmthera.2023.108487"},{"key":"54969_CR17","doi-asserted-by":"publisher","first-page":"15649","DOI":"10.1073\/pnas.202607599","volume":"99","author":"JW Jonker","year":"2002","unstructured":"Jonker, J. W. et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl Acad. Sci. USA 99, 15649\u201315654 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"54969_CR18","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1182\/blood-2004-04-1566","volume":"105","author":"S Zhou","year":"2005","unstructured":"Zhou, S., Zong, Y., Nay, P. A., Nair, G., Stewart, C. F. & Sorrentino, B. P. Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels. Blood 105, 2571 (2005).","journal-title":"Blood"},{"key":"54969_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw6127","volume":"5","author":"P Wang","year":"2019","unstructured":"Wang, P. et al. The essential role of the transporter ABCG2 in the pathophysiology of erythropoietic protoporphyria. Sci. Adv. 5, eaaw6127 (2019).","journal-title":"Sci. Adv."},{"key":"54969_CR20","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1006\/geno.1993.1242","volume":"16","author":"S Boulechfar","year":"1993","unstructured":"Boulechfar, S. et al. Ferrochelatase structural mutant (Fechm1Pas) in the house mouse. Genomics 16, 645\u2013648 (1993).","journal-title":"Genomics"},{"key":"54969_CR21","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1172\/JCI115491","volume":"88","author":"S Tutois","year":"1991","unstructured":"Tutois, S. et al. Erythropoietic protoporphyria in the house mouse. A recessive inherited ferrochelatase deficiency with anemia, photosensitivity, and liver disease. J. Clin. Investig. 88, 1730\u20131736 (1991).","journal-title":"J. Clin. Investig."},{"key":"54969_CR22","first-page":"417","volume":"1","author":"JD Allen","year":"2002","unstructured":"Allen, J. D. et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol. Cancer Therapeutics 1, 417\u2013425 (2002).","journal-title":"Mol. Cancer Therapeutics"},{"key":"54969_CR23","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1124\/mol.113.088609","volume":"84","author":"AE Stacy","year":"2013","unstructured":"Stacy, A. E., Jansson, P. J. & Richardson, D. R. Molecular pharmacology of ABCG2 and its role in chemoresistance. Mol. Pharmacol. 84, 655\u2013669 (2013).","journal-title":"Mol. Pharmacol."},{"key":"54969_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ijd.12016","volume":"53","author":"S Tintle","year":"2014","unstructured":"Tintle, S., Alikhan, A., Horner, M. E., Hand, J. L. & Davis, D. M. R. Cutaneous porphyrias part II: treatment strategies. Int. J. Dermatol. 53, 3\u201324 (2014).","journal-title":"Int. J. Dermatol."},{"key":"54969_CR25","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamadermatol.2017.1557","volume":"153","author":"M Balwani","year":"2017","unstructured":"Balwani, M. et al. Clinical, biochemical, and genetic characterization of north American patients with erythropoietic protoporphyria and X-linked protoporphyria. JAMA Dermatol. 153, 789\u2013796 (2017).","journal-title":"JAMA Dermatol."},{"key":"54969_CR26","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ajhg.2008.08.003","volume":"83","author":"SD Whatley","year":"2008","unstructured":"Whatley, S. D. et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am. J. Hum. Genet. 83, 408\u2013414 (2008).","journal-title":"Am. J. Hum. Genet."},{"key":"54969_CR27","doi-asserted-by":"publisher","first-page":"G1208","DOI":"10.1152\/ajpgi.00505.2004","volume":"288","author":"M Abitbol","year":"2005","unstructured":"Abitbol, M. et al. A mouse model provides evidence that genetic background modulates anemia and liver injury in erythropoietic protoporphyria. Am. J. Physiol. Gastrointest. Liver Physiol. 288, G1208\u2013G1216 (2005).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"54969_CR28","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1124\/dmd.118.083030","volume":"46","author":"H Niall","year":"2018","unstructured":"Niall, H., Parth, K. & Ian, D. K. Polymorphisms of the Multidrug Pump ABCG2: A Systematic Review of Their Effect on Protein Expression, Function, and Drug Pharmacokinetics. Drug Metab. Disposition 46, 1886 (2018).","journal-title":"Drug Metab. Disposition"},{"key":"54969_CR29","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.bbrc.2018.06.157","volume":"503","author":"W Zhang","year":"2018","unstructured":"Zhang, W., Sun, S., Zhang, W. & Shi, Z. Polymorphisms of ABCG2 and its impact on clinical relevance. Biochem. Biophys. Res Commun. 503, 408\u2013413 (2018).","journal-title":"Biochem. Biophys. Res Commun."},{"key":"54969_CR30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/ng.1075","volume":"44","author":"T Zelinski","year":"2012","unstructured":"Zelinski, T., Coghlan, G., Liu, X. Q. & Reid, M. E. ABCG2 null alleles define the Jr(a-) blood group phenotype. Nat. Genet. 44, 131\u2013132 (2012).","journal-title":"Nat. Genet."},{"key":"54969_CR31","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.tetlet.2007.12.130","volume":"49","author":"Y Li","year":"2008","unstructured":"Li, Y., Hayman, E., Plesescu, M. & Prakash, S. R. Synthesis of potent BCRP inhibitor\u2014Ko143. Tetrahedron Lett. 49, 1480\u20131483 (2008).","journal-title":"Tetrahedron Lett."},{"key":"54969_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115666","volume":"259","author":"J Zhu","year":"2023","unstructured":"Zhu, J. et al. Metabolism-guided development of Ko143 analogs as ABCG2 inhibitors. Eur. J. Med. Chem. 259, 115666 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"54969_CR33","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1126\/science.781840","volume":"193","author":"W Trager","year":"1976","unstructured":"Trager, W. & Jensen, J. B. Human malaria parasites in continuous culture. Science 193, 673\u2013675 (1976).","journal-title":"Science"},{"key":"54969_CR34","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.1182\/blood-2004-12-4948","volume":"105","author":"T Tiffert","year":"2005","unstructured":"Tiffert, T. et al. The hydration state of human red blood cells and their susceptibility to invasion by Plasmodium falciparum. Blood 105, 4853\u20134860 (2005).","journal-title":"Blood"},{"key":"54969_CR35","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/jbio.201500195","volume":"9","author":"NA Markwardt","year":"2016","unstructured":"Markwardt, N. A. et al. 405 nm versus 633 nm for protoporphyrin IX excitation in fluorescence-guided stereotactic biopsy of brain tumors. J. Biophotonics 9, 901\u2013912 (2016).","journal-title":"J. Biophotonics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54969-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54969-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54969-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T05:12:27Z","timestamp":1733289147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54969-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["54969"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-54969-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"assertion":[{"value":"8 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X.M., J.Z., and J.L. are inventors on a patent (WO2020236901) and hold equity in Portal Therapeutics, Inc. K.E.A. reports receiving consulting fees, advisory board fees and grants to the university from Alnylam Pharmaceuticals, Recordati Rare Diseases, Mitsubishi Tanabe Pharma America, Disc Medicine and Portal Therapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10557"}}